FLORHAM PARK, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for ...
Cellectar Biosciences (CLRB) and Evestia Clinical have entered into an agreement whereby Evestia will provide Cellectar with full CRO services for their upcoming Phase 1b study evaluating CLR 125 for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback